Navigation Links
Medical societies respond to the FDA's safety announcement on the use of Actos
Date:6/16/2011

Chevy Chase, MD Diabetes leaders today are responding to the announcement made by the U.S. Food and Drug Administration (FDA) yesterday that the use of the diabetes medication Actos (pioglitazone) for more than one year may be associated with an increased risk of bladder cancer. According to the FDA's Safety Announcement, information about this risk will be added to the Warnings and Precautions section of the label for pioglitazone-containing medicines. The patient Medication Guide for these medicines will also be revised to include information on the risk of bladder cancer.

In response to this important safety announcement from the FDA, The Endocrine Society, the American Association of Clinical Endocrinologists and the American Diabetes Association urge patients who are currently taking Actos or any combination of medication that includes pioglitazone, to continue taking all currently prescribed medications unless instructed otherwise by their healthcare provider. Stopping diabetes medications can result in higher levels of blood glucose that may cause serious short term health problems and could increase the risk of diabetes-related complications in the long term.

The Endocrine Society, American Association of Clinical Endocrinologists and American Diabetes Association recommend that patients adhere to the following guidance provided by the FDA:

  • There may be an increased chance of having bladder cancer when taking pioglitazone;
  • Do not take pioglitazone if receiving treatment for bladder cancer;
  • Talk to your doctor right away if you have any of the symptoms of bladder cancer including blood or red color in urine; urgent need to urinate or pain while urinating; pain in back or lower abdomen;
  • Read the Medication Guide included with pioglitazone medicine as it explains risks associated with the use of the drug; and
  • Talk to your healthcare professional if you have questions of concerns about pioglitazone medicines.

According to the FDA Safety Announcement, the five-year interim analysis of an ongoing ten-year study showed that although there was no overall increased risk of bladder cancer with pioglitazone use, an increased risk of bladder cancer was noted among patients who had been on pioglitazone the longest and had been on higher doses over time.

The Endocrine Society, the American Association of Clinical Endocrinologists and the American Diabetes Association continue to support the FDA in its role as the regulatory agency that makes decisions regarding drug safety and efficacy.


'/>"/>

Contact: Arlyn Riskind
ariskind@endo-society.org
301-941-0240
The Endocrine Society
Source:Eurekalert

Related medicine news :

1. TheReliefPlace.com Launches Online Store “The Relief Shop” - What Does this Medical Supply Store Carry and How Can They Help You?
2. Medical Transcription Services and EHR Provider MxSecure Launches New Enhanced Website with Goal of Improved Physician Productivity
3. Medical Training School, Pima Medical Institute Offering First Bachelor's Degree Program
4. FDA Seeks Reduction in Radiation From Medical Scans
5. UH Case Medical Center researchers publish promising findings for advanced cervical cancer
6. University of Virginia Health System Medical Laboratories Selects Sunquest's Specimen Collection Solution
7. Medical Imaging Northwest Completes Phase I of Its Healthcare IT Integration to Maintain Patient Care Improvements
8. Centene Corporation Hosts Medical Management Systems Update in New York City
9. CelebrityDiagnosis.com Nominated as Best New Medical Blog of 2009
10. Medical Malpractice Survivors Urge President Obama to Keep Tort Reform out of Health Insurance Bill
11. Tufts Medical Center and Boston Medical Center Nurses Hold a Joint Informational Picket to Protest Unsafe Staffing and Practice Conditions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... February 05, 2016 , ... Successful recruitment ... new clinical and scientific initiatives have all marked the last 12 months at ... and CEO of the nation’s oldest cancer center, Candace S. Johnson, PhD, outlined ...
(Date:2/5/2016)... York, New York (PRWEB) , ... February 05, 2016 , ... ... life? The answer may be at the tips of your toes. Foot massage, whether ... as well as pure comfort and relaxation. The American Board of Multiple Specialties ...
(Date:2/5/2016)... ... February 05, 2016 , ... US Sports Camps ... in Dover, NH to direct high-performance kids yoga training. ChildLight Yoga Studio is centrally ... one hour from Boston. , ChildLight Yoga Studio founder Lisa Flynn expresses her excitement, ...
(Date:2/5/2016)... ... February 05, 2016 , ... Give To Cure ... search for and donate to Give To Cure’s campaign that is crowdfunding clinical trials ... users make and share payments through a smart device. In 2015 alone, Venmo processed ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Dr. Justin ... announce their 2nd Annual No Cost Dental Day to individuals in need. The event ... purpose of this No Cost Dental Day is to provide dental care to community ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... , Feb. 4, 2016  SciClone Pharmaceuticals, Inc. ... it has entered into a settlement agreement with ... fully resolving the SEC,s investigation into possible violations ... the terms of the settlement agreement, SciClone has ... including disgorgement, pre-judgment interest and a penalty.  This ...
(Date:2/4/2016)... Feb. 4, 2016 Global Immunology Market ... to drive long-term market growth Summary ... of chronic disorders that affect 5–7% of western ... of their symptoms and key patient demographics, they ... immune pathways and an inappropriate immune response. Generally, ...
(Date:2/4/2016)... DIEGO, Feb. 4, 2016  Aethlon Medical, Inc. ... affinity biofiltration devices to treat life-threatening diseases, today ... 2016 ended December 31, 2015. ... objectives set forth in our last quarterly call, ... reinforce our long-term objective to establish the Aethlon ...
Breaking Medicine Technology: